Michael Hölzel
Prof. Dr. Michael Hölzel
  • Institut für Experimentelle Onkologie
  • cancer research
  • tumor microenvironment
  • computational modeling
Long-standing interest in cancer research with a special focus on tumor microenvironment and cancer immunotherapy. We use different types of pre-clinical models including patient-derived tumor organoids trying to understand mechanisms of therapy resistance to current and novel treatment. In close cooperation with groups from computational biology and mathematics we aim at establishing novel approaches and models to analyze and simulate tumor and immune cell phenotype dynamics in the tumor microenvironment under immunotherapy.
Ausgewählte Publikationen

Glodde N et al. (2017) Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity 47:789-802.e9.

Reinhardt J et al. (2017) MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res 77:4697–4709.

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M (2015) MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun 6:8755.

Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142:218–229.

Michael Hölzel
Prof. Dr. Michael Hölzel
Wird geladen